KDR and nonpapillary renal cell carcinoma: Given the important role of angiogenesis in ccRCC, antiangiogenic drugs have been used as a major therapeutic approach for advanced ccRCC, mainly including antibodies against VEGF and tyrosine kinase inhibitors targeting VEGFR or other kinases25,37.